ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.
IPO Year:
Exchange: NASDAQ
Website: prophaselabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $12.00 → $15.00 | Buy | HC Wainwright & Co. |
| 12/20/2021 | $12.00 | Buy | HC Wainwright & Co. |
| 10/13/2021 | Buy → Neutral | Dawson James |
EFFECT - ProPhase Labs, Inc. (0000868278) (Filer)
10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
S-3 - ProPhase Labs, Inc. (0000868278) (Filer)
424B5 - ProPhase Labs, Inc. (0000868278) (Filer)
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
424B5 - ProPhase Labs, Inc. (0000868278) (Filer)
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W
Sidus Space (NASDAQ:SIDU) (the "Company" or "Sidus"), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White will oversee the Company's accounting, financial planning, capital raise, treasury, legal and regulatory functions. Mr. White has more than 30 years of experience in financial management, operations, and business development. He most recently served as Chief Financial Officer of ProPhase Labs, Inc. (NASDAQ:PRPH) and prior to ProPhase he was CFO, treasurer, and secretary of Intellicheck, Inc., a technology company listed on the NasdaqGM. Mr. White has broad domestic and int
GARDEN CITY, NY, Oct. 17, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a growth-oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board. Dr. Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and Computer Science, and past chair of the Bioengineering Department at Stanford University. Dr. Altman is the second member of Nebula's Advisory Board and joins Dr. George Church, Nebula's Founder and Advisory Board Chairman. Nebula Genomics, a global leader in direct-to-consumer whole genome se
Garden City, NY, May 10, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a diversified diagnostics and genomics company, announced today that Bill White has been appointed Chief Financial Officer (CFO) of ProPhase Labs, effective May 23, 2022. Mr. White joins ProPhase Labs from Intellicheck, Inc., where he served as Chief Financial Officer, Treasurer and Secretary since April 2012 and Chief Operating Officer since March 2020. Mr. White has more than 30 years of experience in financial management, operations and business development. Prior to joining Intellicheck, he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. ("FM"). As co-foun
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future. Dear Impact Biomedical Inc. (IBO) Shareholders, We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ:PRPH). The update note includes information on ProPhase's business model, services offered, industry outlook, financial results, management commentary, valuation, and risks. The update note is available below. ProPhase Labs November 2024 Update Note Highlights from the note include: Launch of Direct-to-Consumer DNA Complete and DNA Expand Genetic Testing Offerings: In Q3 FY2024, ProPhase Labs launched two significant product offerings, DNA Complete and DNA Expand, under it
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended September 30, 2024. The Company also highlighted substantial progress in its ongoing strategic initiatives, which are expected to drive significant revenue growth a
GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and diagnostics company, today announced the closing of its previously announced underwritten public offering of 4,795,500 shares of its common stock, including 625,500 shares sold upon full exercise of the underwriter's option to purchase additional shares. Each share of common stock was sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3.45 million, before deducting underwriting discounts and offering expenses. All of the shares were sold by the Company. The Company intends to use the net proceeds f
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less d
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or Pre-Funded Warrants sold in this offering to cover over-allotments, if any. All of the shares of common stock (and/or Pre-Funded Warrants) are being offered by the Company. The offering is subject to market conditions and the
Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer's genome. This new service provides customers with in-depth insights into health, wellness, and ancestry. DNA Complete – A New Paradigm in Direct-to-Consumer DNA Testing Comprehensive Whole Genome Sequencing: Unlike trad
GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to connect.". Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 1PM ET on October 30th. One-on-one investor meetings will be held throughout the day. Interested investors c
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer Test GARDEN CITY, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics, and diagnostics company, today announced significant progress across several key projects. Pharmaloz Manufacturing Inc. (PMI): In Q3, the Company engaged ThinkEquity as an advisor to pursue strategic alternatives for PMI. ThinkEquity has now identified more than 70 potential acquirers for PMI, with a goal of negotiating and finaliz
PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value CreationGarden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. ("PMI"), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. The Company believes that the strategic enhancements to PMI's primary production line have generated increased capacit
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.18) by 61.11 percent. The company reported quarterly sales of $3.634 million which missed the analyst consensus estimate of $9.860 million by 63.14 percent. This is a 81.17 percent decrease over sales of $19.303 million the same period last year.
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (WGS)
ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs, commented, "The BE-Smart test is more than an advancement in medical technology; it is providing a critical solution to esophageal cancer by enabling early and cost-effective detection. Early detection offers patients the opportunity for more favorable outcomes and a brighter, healthier future. This groundbreaking diagnostic test is a patent-protected met
ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.26) by 96.15 percent. This is a 537.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $4.35 million which missed the analyst consensus estimate of $10.69 million by 59.30 percent. This is a 80.06 percent decrease over sales of $21.82 million the same period last year.
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on revenue of $7.83 million. • NeoGenomics (NASDAQ:NEO) is likely to report quarterly earnings at $0.17 per share on revenue of $182.13 million. • Prestige Consumer (NYSE:PBH) is estimated to report quarterly earnings at $1.20 per share on revenue of $1.61 billion. • Hibbett (NASDAQ:HIBB) is projected to report quarterly earnings at $2.55 per share on revenue of $477.49 million. • RLX Technology (NYSE:RLX) is expected to report quarterly earnings at $0.02 per share on revenue of $66.52 million. • KVH Industries (NASDAQ:KVHI) is expected to report quarterly loss at $0
ProPhase Labs (NASDAQ:PRPH) is set to give its latest quarterly earnings report on Friday, 2024-03-15. Here's what investors need to know before the announcement. Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $-0.26. ProPhase Labs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company missed EPS by $0.11, which was followed by a 10.78% drop in the shar
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $11 price target.
ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics and diagnostics company, today announced important developments in the Company's efforts to commercialize its novel BE-SMART esophageal cancer diagnostic test. BE-Smart is a novel diagnostic test that is intended to detect and quantify early signs of certain types of cancer in individuals with Barrett's esophagus, a condition known to significantly increase the risk of developing esophageal cancer. This breakthrough test, in development for nearly five years, is nearing completion of clinical studies. If the clinical trial results are successful, the Company will be aiming for commercial launch during 2024. Recently, a
HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously
HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00
Dawson James downgraded ProPhase from Buy to Neutral
Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended September 30, 2024. The Company also highlighted substantial progress in its ongoing strategic initiatives, which are expected to drive significant revenue growth a
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay
Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun in Q3 2024 and Potential Sale of Business Announces Major DTC Initiatives for Nebula Genomics, anticipating new sales ramp in Q4 2024 Company to hold a virtual conference call Wednesday, August 14, 2024, at 11:00 AM ET GARDEN CITY, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2024. The Company also highlighted subs
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's Investor website. REGISTER HERE: https://www.renmarkfina
GARDEN CITY, NY, May 02, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), announced today that they will be presenting first quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on May 9, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's Investor website. REGISTER HERE: https://w
GARDEN CITY, NY, March 08, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), announced today that they will be presenting full year 2023 financial results on a virtual conference call hosted by Renmark Financial on March 15, 2024 at 11:00 am EDT. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a replay will be available on The Company's Investor website. REGISTER HERE: https://www.renmarkfinancial.com/events/fourth-quarter-year-end-2023-results-virtual-conference-call-nasdaq-prph-2024-03-
GARDEN CITY, NY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, November 9, 2023, at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period. To access the call, please use the following information: Date:Thursday, November 9, 2023Time:11:00 a.m. Eastern time, 8
Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) Conference Call and Webcast Details Management will host a conference call at 11:00 AM ET, Thursday, August 10, 2023, to provide an update on corporate developments and review financial results. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10181498/fa179afdde Please note that registered participants will receive their dial-in number upon registration and may dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by
GARDEN CITY, NY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics, therapeutics and diagnostics company, will hold a conference call on Thursday, August 10, 2023, at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2023 and provide a business update. A press release detailing these results will be issued prior to the call. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period. To access the call, please use the following information: Date:Thursday, August 10, 2023Time:11:00 a.m. Eastern time, 8:00 a.m. Pa
GARDEN CITY, NY, May 04, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics and diagnostics company, will hold a conference call on Thursday, May 11, 2023, at 11:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2023. A press release detailing these results will be issued prior to the call. ProPhase Labs' CEO and Chairman of the Board of Directors, Ted Karkus, will host the conference call, followed by a question-and-answer period. To access the call, please use the following information: Date: Thursday, May 11, 2023Time: 11:00 a.m. Eastern time, 8:00 a.m. Pacific time Participants can register for the conferenc
4/A - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
3 - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
4/A - ProPhase Labs, Inc. (0000868278) (Issuer)
4/A - ProPhase Labs, Inc. (0000868278) (Issuer)
4/A - ProPhase Labs, Inc. (0000868278) (Issuer)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)